pharma · Prostate Cancer
Myovant Sciences
Myovant Sciences GmbH
Myovant Sciences is a pharma organization headquartered in CN. Primary therapeutic focus areas include Prostate Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Relugolix
Phase 3 · small molecule · Prostate Cancer
Relugolix for Prostate Cancer is a Phase 3 program (small_molecule) at Myovant Sciences GmbH with 1 ClinicalTrials.gov record(s).
Internal code MVT-601-3201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Myovant Sciences GmbH
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Prostate Cancer
- Status
- completed
- Trials
- 1